Faculty

Program Schedule — Central Time

5:30 AM – 6:00 AM — Registration and Dinner
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD)

• Risk factors for the development of pancreatic cancer, such as family history/ genetic predisposition syndromes, smoking, obesity/diet and metabolic diseases
• Rationale for the high proportion of PAD cases diagnosed in the advanced stages of the disease
• Factors contributing to the aggressive nature of PAD; prognosis associated with advanced disease
• Common presenting symptoms of PAD, such as asthenia, anorexia/weight loss, pain and jaundice
• Importance of palliative care for patients with advanced PAD

MODULE 2: Recent Advances in Up-Front Treatment for Metastatic PAD

• Impact of age, performance status, comorbidities, patient preferences and prior (neo)adjuvant therapy, if any, on the choice of first-line treatment for metastatic PAD
• Historical data establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
• Proposed mechanism of improved delivery of cytotoxic therapy to pancreatic cancer cells with nanoliposomal irinotecan (nal-IRI) compared to conventional chemotherapy
• Key efficacy and safety outcomes reported with nal-IRI, fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for previously untreated metastatic PAD
• FDA approval of up-front NALIRIFOX for patients with metastatic PAD; selection of optimal candidates for this regimen

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Metastatic PAD

• Key factors influencing the selection and sequencing of available therapies for R/R metastatic PAD
• Long-term efficacy and safety findings with nal-IRI in combination with 5-FU/LV after disease progression on gemcitabine-based therapy
• Patient selection for and practical integration of nal-IRI in the R/R setting
• Other evidence-based chemotherapeutic agents or regimens for patients with progressive metastatic PAD

MODULE 4: Tolerability and Other Practical Considerations with Nanoliposomal Irinotecan (Nal-IRI) and Other Cytotoxic Approaches

• Comparative tolerability/toxicity profile of NALIRIFOX and other commonly employed first-line regimens, such as FOLFIRINOX and gemcitabine/nab paclitaxel
• Rates of diarrhea and other gastrointestinal (GI) issues documented with nal-IRI; indications for prophylactic antidiarrheals and antiemetics for patients who are about to start treatment
• Incidence and severity of cytopenias with nal-IRI; role of growth factor use and appropriate monitoring of complete blood counts during therapy
• Recommended dosing of nal-IRI as part of the first-line NALIRIFOX regimen versus in the R/R setting
• Effect of dose adjustment on the efficacy of first-line NALIRIFOX; implications for the feasibility of tolerability-guided dosing strategies

MODULE 5: Novel Strategies Targeting RAS Mutations in Advanced PAD

• Incidence and spectrum of RAS mutations in PAD; impact on patient outcomes
• Mechanism of antitumor activity of the RAS(ON) multiselective inhibitor daraxonrasib and rationale for its investigation in advanced PAD
• Early efficacy outcomes with daraxonrasib as monotherapy and in combination with gemcitabine/nab paclitaxel for patients with previously treated and treatment-naïve advanced PAD harboring RAS mutations
• FDA breakthrough therapy designation for daraxonrasib for previously treated KRAS G12-mutant advanced PAD
• Ongoing and planned Phase III trials of daraxonrasib alone or in combination with chemotherapy for patients with PAD

MODULE 6: Tolerability of RAS-Targeted Therapies Under Investigation for Advanced PAD

• Incidence, time to onset and severity of GI side effects (eg, diarrhea, nausea, vomiting, stomatitis/mucositis, liver enzyme elevations) with daraxonrasib for patients with PAD
• Spectrum, incidence and severity of daraxonrasib-associated dermatologic issues, including rash, dry skin, paronychia and others
• Strategies to mitigate, monitor for and manage potential treatment-emergent adverse events (AEs) with daraxonrasib should it become available
• Impact on the tolerability of daraxonrasib when combined with chemotherapy

MODULE 7: Potential Utility of Tumor Treating Fields (TTFields) in the Management of PAD

• Mechanism of action of TTFields and biological rationale for their investigation in PAD
• Antitumor activity reported with TTFields in combination with gemcitabine and nab paclitaxel as first-line treatment for unresectable, locally advanced PAD
• Recent FDA approval of TTFields for locally advanced PAD; integration into clinical algorithms
• Ongoing evaluation of TTFields in combination with atezolizumab, gemcitabine and nab paclitaxel as first-line treatment for metastatic PAD

MODULE 8: Tolerability and Other Practical Considerations with TTFields

• Components of the TTFields system; placement of arrays for patients with PAD
• Appropriate skin preparation prior to array placement and during array changes with TTFields
• Spectrum, incidence and severity of dermatologic AEs documented with TTFields; appropriate mitigation and management strategies
• Other practical considerations associated with TTFields use, such as appropriate duration of treatment per day, bathing procedures and ability to travel

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and potential clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available data with and ongoing research studies of novel agents designed to exploit this emerging therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PancreaticCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip — Advisory Committees: Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Revolution Medicines Inc; Consulting Agreements: Novocure Inc; Contracted Research: Bristol Myers Squibb, Novartis, Revolution Medicines Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committees: J-Pharma Co Ltd, Oncolytics Biotech Inc.

MODERATOR — Dr O’Reilly — Advisory Committees and Consulting Agreements (Uncompensated): Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Tango Therapeutics; Contracted Research: Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, Tango Therapeutics; Nonrelevant Financial Relationships: American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), Stand Up 2 Cancer.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Ipsen Biopharmaceuticals Inc and Revolution Medicines Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (NMIBC)

• Current management algorithms for NMIBC; key findings informing the selection of patients with bacillus Calmette-Guérin (BCG)-unresponsive NMIBC for pembrolizumab therapy
• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for BCG-naïve, high-risk NMIBC
• Available efficacy and safety data with durvalumab and sasanlimab, respectively, in combination with BCG for BCG-naïve, high-risk NMIBC
• Potential role of anti-PD-1/PD-L1 antibodies with BCG for BCG-naïve, high-risk NMIBC

MODULE 2: Perioperative Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)

• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies administered perioperatively for MIBC
• Key efficacy and safety findings documented with neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for MIBC
• FDA approval of durvalumab as a component of perioperative systemic therapy for MIBC
• Selection of appropriate candidates with MIBC for perioperative durvalumab therapy; role, if any, for patients with preexisting autoimmune conditions, compromised renal function, et cetera

MODULE 3: Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC

• Pathophysiology, spectrum, frequency, severity and timing of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies
• Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other therapies (eg, BCG, chemotherapy, enfortumab vedotin)
• Optimal monitoring for immune-related and other potential AEs with immune checkpoint inhibitors; importance of prompt reporting of symptoms
• Recommended algorithms for the management of various immune-related AEs by grade/severity

MODULE 4: Novel Intravesical Therapies for Nonmetastatic UBC

• Advantages of intravesical delivery systems to administer systemic therapies for nonmetastatic UBC
• Available findings with the gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC in patients who are ineligible for or decline radical cystectomy
• FDA approval of the gemcitabine intravesical system for the treatment of BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors; selection of appropriate candidates for this strategy
• Initial safety and efficacy results with the erdafitinib intravesical delivery system TAR-210 for patients with NMIBC and select FGFR alterations
• Ongoing Phase III evaluations of the gemcitabine intravesical system and TAR-210 for nonmetastatic UBC

MODULE 5: Tolerability/Toxicity Profile of and Other Practical Considerations with Novel Intravesical Therapies

• Importance of pretreatment evaluation of bladder integrity for patients about to receive intravesical therapy
• Logistics of insertion and removal of the gemcitabine intravesical system and TAR-210
• Incidence of urinary issues (eg, urinary frequency, urinary tract infection/pain, dysuria, micturition urgency, hematuria) related to the gemcitabine intravesical system; optimal strategies to mitigate these effects
• Spectrum, frequency and severity of systemic toxicities with the gemcitabine intravesical system (eg, myelosuppression, other laboratory abnormalities, pneumonia); appropriate monitoring and management protocols
• Incidence, severity and management of local and systemic side effects noted with TAR-210

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
• Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
• Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
• Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
• Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
• Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
• Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Drakaki — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Nektar Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Stock OPTIONS — Private Companies: Athos Therapeutics; Nonrelevant Financial Relationships: Dyania Health.

MODERATOR — Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Hormonal Therapy for Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

• Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
• Key findings, including overall survival outcomes, with enzalutamide combined with leuprolide versus enzalutamide or leuprolide alone for men with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) for nmHSPC
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

MODULE 2: Hormonal Therapy for Metastatic HSPC (mHSPC)

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for men with mHSPC
• Published data with the addition of darolutamide to ADT for patients with mHSPC; recent FDA approval of this regimen
• Clinical factors guiding the selection of a specific secondary hormonal agent for patients with mHSPC; available datasets exploring the relative benefit of the various approved therapies in this setting
• Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy

MODULE 3: Tolerability of Hormonal Therapy for Prostate Cancer

• Incidence of hypertension and other cardiovascular (CV) adverse events (AEs) with different hormonal agents; optimal pretreatment assessment, on-therapy monitoring and management of CV events
• Spectrum and frequency of central nervous system-related AEs (eg, seizures, cognitive decline, falls, fatigue) observed with hormonal therapy for patients with prostate cancer
• Prevalence, mitigation and management of other notable side effects (eg, fractures, hot flashes, sarcopenias) with available hormonal therapies for prostate cancer
• Tolerability profile of enzalutamide with and without ADT for nmHSPC; differences, if any, in the experience with this agent in later settings

MODULE 4: Potential Role of Capivasertib in the Management of mHSPC

• Frequency of PTEN deficiency in patients with prostate cancer; optimal approach to assessment of PTEN status
• Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease; mechanism of action of capivasertib
• Recently presented efficacy and safety results with the addition of capivasertib to abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Potential integration of capivasertib/abiraterone/ADT into treatment algorithms

MODULE 5: Tolerability Profile of Capivasertib

• Recommended side-effect management strategies for patients experiencing diarrhea and other gastrointestinal (GI) disorders while receiving capivasertib
• Incidence of hyperglycemia among patients receiving capivasertib; appropriate glucose monitoring and interventions for those with elevated blood glucose levels
• Optimal mitigation and management of cutaneous adverse reactions associated with capivasertib
• Appropriate monitoring of complete blood counts for patients receiving capivasertib; recommended dose modifications for those experiencing cytopenias

MODULE 6: Current and Future Role of PARP Inhibitors in Therapy for Metastatic Prostate Cancer

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in prostate cancer; recommended timing and optimal method for genetic testing
• Biological basis for combining PARP inhibitors with secondary hormonal therapies in metastatic prostate cancer
• Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide in mCRPC; optimal selection of patients for these approaches
• Recently presented data with the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications and integration into treatment algorithms
• Other ongoing Phase III efforts evaluating combined PARP/AR pathway inhibition in this setting

MODULE 7: Tolerability of PARP Inhibitors Used for Prostate Cancer

• Incidence, timing and severity of common class-effect and agent-specific toxicities associated with PARP inhibitors for patients with metastatic prostate cancer
• Optimal monitoring and management strategies for PARP inhibitor-related toxicities
• Impact on the tolerability of PARP inhibitors when administered in combination with secondary hormonal therapy
• Strategies for identifying the root cause of toxicities in patients receiving PARP inhibitor/secondary hormonal therapy combinations that may be attributable to either agent

MODULE 8: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Prostate Cancer

• Clinical relevance of PSMA expression in prostate cancer; mechanism of action of lutetium Lu 177 vipivotide tetraxetan
• Published datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated PSMA-positive mCRPC
• Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan with regard to other available therapies for mCRPC
• Recently presented data with the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice

MODULE 9: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan in Treatment for Metastatic Prostate Cancer

• Incidence, severity and management of commonly occurring AEs with radium-223 (eg, cytopenias, GI toxicity, peripheral edema, fractures)
• Recommended algorithms for the management of common AEs observed in patients receiving lutetium Lu 177 vipivotide tetraxetan (eg, fatigue, dry mouth, GI toxicity, cytopenias)
• Educating patients receiving radiopharmaceuticals regarding radiation risks and appropriate protection precautions
• Other practical considerations related to the administration of novel radiopharmaceuticals for prostate cancer (eg, locating and referring patients to a nuclear medicine treatment center)

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise published research findings on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, and apply this information to educate patients about personalized treatment recommendations.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and identify patients for these strategies.
• Assess the available research supporting PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ProstateCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Mr Lai and Ms Walker have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Yu — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, Tyra Biosciences Inc. 

MODERATOR
Dr Tagawa — Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

• Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
• Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
• Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
• Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

MODULE 2: First-Line Therapy for Advanced or Recurrent EC

• Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
• Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

• Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
• Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
• Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
• Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
• Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
• Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
• Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
• Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

• Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
• Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
• Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
• Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

• Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
• Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
• Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
• Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
• Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
• Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen — Speakers Bureaus: Amgen Inc.

MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

• Similarities and differences between germline and somatic genetic mutations
• Incidence and clinical significance of BRCA mutations and other germline or somatic alterations (eg, PALB2, ATM, RAD51C/D) in ovarian cancer
• Current roles of next-generation sequencing and germline sequencing for advanced ovarian cancer; similarities and differences among available genetic testing platforms
• Purpose and potential benefits of genetic counseling after a diagnosis of ovarian cancer

MODULE 2: Role of PARP Inhibitors for Advanced Ovarian Cancer

• Mechanism of antitumor activity of PARP inhibitors, and rationale for their use as maintenance therapy for patients with newly diagnosed advanced ovarian cancer
• Long-term findings from Phase III studies with olaparib, olaparib/bevacizumab and niraparib maintenance for newly diagnosed ovarian cancer
• Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab or niraparib maintenance
• Current clinical utility, if any, of PARP inhibitors for relapsed/refractory ovarian cancer, including among patients who have experienced disease progression on or after prior PARP inhibitor therapy

MODULE 3: Side Effects and Other Practical Considerations with PARP Inhibitors

• Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
• Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with ovarian cancer
• Optimal monitoring and management paradigms for common PARP inhibitor-related toxicities
• Long-term risk of acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
• Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

MODULE 4: Current and Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment

• Frequency of and scientific rationale for targeting folate receptor alpha (FRα) in ovarian cancer
• Mechanism of action and structural components of mirvetuximab soravtansine
• Published research findings with mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer
• FDA approval of mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer; implications for biomarker assessment and current management
• Early findings with mirvetuximab soravtansine for FRα-high, platinum-sensitive advanced ovarian cancer; ongoing evaluation and potential utility in this setting

MODULE 5: Toxicities Associated with Mirvetuximab Soravtansine

• Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
• Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
• Importance of collaboration with eye care specialists for patients receiving mirvetuximab soravtansine
• Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

MODULE 6: Other Approved and Investigational Antibody-Drug Conjugates for Ovarian Cancer

• Frequency of HER2 expression in advanced ovarian cancer; optimal timing of and approach to testing
• FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for ovarian cancer management
• Biological rationale for targeting CDH6 for ovarian cancer; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
• Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced ovarian cancer

MODULE 7: Current Role of Relacorilant for Advanced OC

• Incidence and clinical relevance of glucocorticoid receptor (GR) overexpression in ovarian cancer
• Mechanism of action of the selective GR modulator relacorilant; rationale for combining relacorilant with chemotherapy for advanced ovarian cancer
• Published efficacy and safety findings with relacorilant in combination with nab paclitaxel versus nab paclitaxel alone for platinum-resistant advanced ovarian cancer
• Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant advanced ovarian cancer, and integration into current clinical algorithms

MODULE 8: Tolerability Considerations with Relacorilant/Nab Paclitaxel

• Rationale for nab paclitaxel as a therapeutic partner for relacorilant; necessity of avoiding corticosteroid use with relacorilant
• Tolerability profile of relacorilant/nab paclitaxel in published clinical trials; relative contributions of each agent in terms of toxicities
• Incidence and severity of cytopenias with relacorilant/nab paclitaxel; appropriate monitoring and management
• Rates of and strategies to manage peripheral neuropathy with relacorilant/nab paclitaxel

MODULE 9: Utility of Immune Checkpoint Inhibition for Advanced OC

• Historical outcomes documented with anti-PD-1/PD-L1 antibodies as monotherapy for advanced ovarian cancer; potential explanations for the lack of activity with these agents for ovarian cancer relative to other tumor types
• Emerging data demonstrating a progression-free survival advantage with the addition of pembrolizumab to chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer
• Impact of PD-L1 expression on overall survival in the aforementioned emerging data set; potential implications for biomarker analysis for advanced ovarian cancer
• Potential clinical role of pembrolizumab for platinum-resistant recurrent ovarian cancer

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and counsel appropriate individuals regarding personalized treatment recommendations.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
• Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
• Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
• Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
• Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
• Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR — Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

10:45 AM – 11:15 PM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting

MODULE 1: Rationale for the Use of Antibody-Drug Conjugates (ADCs) as Cancer Treatment

• Rationale for conjugating monoclonal antibodies with cytotoxic drugs to form ADCs; theoretical improvement of chemotherapy efficacy while reducing systemic exposure and toxicity
• Structural components, such as antibodies, linkers and cytotoxic payloads, of commercially available and investigational ADCs
• Direct mechanism of antitumor activity of ADCs and other means by which they can elicit an antitumor effect, such as bystander killing

MODULE 2: Current and Future Role of ADCs in Cancer Therapy

• FDA-approved indications for ADCs in various tumor types
• Clinical significance of FDA breakthrough therapy designation and current ADCs in development receiving this distinction
• Biological rationale for combining ADCs with other cancer therapies (eg, immune checkpoint inhibitors) and current and future role of this strategy in treatment
• Emerging findings with and ongoing studies evaluating ADCs for patients with non-metastatic disease
• Other promising investigational ADCs in clinical development

MODULE 3: Practical Considerations with ADCs

• Setting patient expectations regarding ADC efficacy and tolerability
• Optimal timing for initiation of approved ADCs or consideration of a clinical trial evaluating 1 of these agents
• ADC effectiveness for patients with CNS metastases
• Mechanisms of resistance to ADCs; feasibility of using multiple agents in this class sequentially for the same patient

MODULE 4: Cytopenias Associated with ADCs

• Educating patients regarding the capacity of ADCs to cause acute “chemotherapy-like” side effects
• Incidence and severity of neutropenia, thrombocytopenia and anemia with approved and investigational ADCs
• Indications for prophylactic growth factor use for patients who are about to start treatment with an ADC
• Appropriate monitoring of complete blood counts during ADC therapy; thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias

MODULE 5: Gastrointestinal (GI) Adverse Events (AEs) Documented with ADCs

• Rates of various GI issues (eg, nausea, vomiting, diarrhea, constipation, abdominal pain) in patients receiving ADC therapy
• Indications for prophylactic antiemetics and antidiarrheals for patients who are about to start treatment with an ADC
• Role of nutritional counselling and diet modifications during ADC treatment
• Potential advantages of complementary therapies, such as acupuncture and yoga, in managing GI side effects of ADCs

MODULE 6: Recognition and Management of Interstitial Lung Disease (ILD)/Pneumonitis Associated with ADCs

• Pathophysiology of ILD/pneumonitis associated with ADCs; baseline risk factors for its development
• Rates, severity and timing of ILD/pneumonitis in clinical trial experiences with various ADCs
• Appropriate workup for patients suspected of experiencing therapy-related ILD/pneumonitis; strategies to distinguish drug-related pulmonary toxicity from other potential causes
• Guidelines for treatment modifications and discontinuation for patients experiencing ILD/pneumonitis; indications for restarting ADC therapy after resolution
• Utility of other supportive care measures, such as corticosteroids and oxygen supplementation, for patients experiencing ILD/pneumonitis

MODULE 7: Potential for Mucositis/Stomatitis with ADCs

• Incidence and severity of mucositis/stomatitis with various approved and investigational ADCs
• Counseling patients on the importance of oral hygiene during treatment with ADCs known to cause mucositis/stomatitis
• Role of steroid mouthwash, prophylactic antibiotics/antifungals and pain medications for patients who are at risk for or are experiencing mucositis/stomatitis
• Dietary recommendations for patients experiencing mucositis/stomatitis

MODULE 8: Ocular Toxicities with ADCs

• Pathophysiology of ocular AEs associated with certain ADCs; spectrum, incidence and severity of ocular toxicities with different agents
• Optimal patient counseling and education regarding signs of ocular toxicity and the importance of early reporting of symptoms
• Utility of other prophylactic and supportive care measures to mitigate and manage ocular toxicities
• Importance of interdisciplinary coordination with eye-care professionals in the identification and management of treatment-related ocular AEs

MODULE 9: Cardiovascular AEs Associated with Select ADCs

• Pathophysiology of the cardiotoxicity associated with anti-HER2 therapies, including ADCs
• Incidence of left ventricular dysfunction noted with HER2-targeted ADCs in clinical trial experiences
• Appropriate monitoring of left ventricular ejection fraction (LVEF) at baseline and during treatment with HER2-targeted ADCs
• Threshold for treatment interruption for patients experiencing LVEF decrease; indications for restarting HER2-targeted ADC therapy after recovery
• Role of interdisciplinary coordination with cardiologists when monitoring for and managing cardiac toxicities associated with HER2-targeted ADCs

MODULE 10: Other Toxicities Reported with 1 or More ADCs

• Incidence and management of peripheral neuropathy associated with various ADCs
• Rates of alopecia reported with ADC treatment; available strategies to reduce the incidence/severity of hair loss or limit its psychosocial impact (eg, scalp-cooling methods, wigs/hair pieces)
• Available strategies to ameliorate the symptoms of rash and other cutaneous reactions associated with ADCs (eg, antihistamines, topical steroids, emollients)
• Spectrum of other toxicities (eg, fatigue, hemorrhage, effusion/edema, hyperglycemia) associated with 1 or more ADCs used in the treatment of cancer

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider the scientific justification for antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the differential targets, structural components and mechanisms of activity of different clinically available and investigational ADCs.
• Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
• Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
• Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs demonstrating efficacy in the management of various tumor types, and educate patients about to commence therapy with these approaches regarding the potential development of adverse events and what to do if they are suspected.
• Recall strategies commonly employed to identify, manage and mitigate toxicities resulting from anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
• Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of various ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ADCs/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Arn — Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc. Ms Carroll — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis. Dr Garon — Consulting Agreements: AbbVie Inc, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, Hexagon Bio, I-Mab Biopharma, IO Biotech, iTeos Therapeutics, LianBio, Merck, Novartis, Oxford BioTherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Samsung Bioepis, Sanofi, Servier Pharmaceuticals LLC, Strata Oncology, Synthekine, TransCode Therapeutics, Verastem Inc; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics, Nuvalent, Servier Pharmaceuticals LLC. Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

MODERATOR — Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.